The value of chitosan as a natural preservative in the food industry stems from its unique film-forming properties and antibacterial mechanism. Studies show that treating the surface of fruits with a 1.5% chitosan solution can form a microporous film with a thickness of only 0.03 millimeters, reducing the oxygen permeability by 40% and increasing the carbon dioxide permeability by 25%, thereby controlling the rot rate of strawberries from 25% to within 8%. In its fresh-cut fruit product line launched in 2023, Nestle has extended the shelf life from 7 days to 14 days through chitosan coating technology, reducing the loss rate by 18% and saving approximately 3 million US dollars in cold chain costs annually. This biopolymer is like putting on an “intelligent protective coat” for food. Its antibacterial activity can inhibit Gram-negative bacteria by up to 90%, and it fully complies with the EU EFSA food safety standard No. 401/2013.
The key reason why pharmaceutical enterprises favor chitosan chitosan lies in its controllable bioadhesion and enhanced mucosal permeability. Pfizer’s insulin nasal delivery system shows that adding 0.8% chitosan with a deacetylation degree of 85% can increase the drug’s bioavailability from 15% to 55% and shorten the peak absorption time to 12 minutes. According to the clinical data from the International Journal of Pharmaceutics, the gastric retention tablets containing chitosan can stay in the stomach for up to 6 hours. The fluctuation range of the drug release curve has been optimized from ±40% to ±15%, increasing the proportion of time when the blood concentration of antihypertensive drugs remains stable within the treatment window from 65% to 90%. This carrier system is like setting up a “drug navigator” in the digestive tract, and the binding force between its positively charged amino groups and the negatively charged regions of the mucosa is as high as 20 millinewtons per meter.
From the perspective of formula economics, the multi-functional characteristics of chitosan can significantly reduce the overall production cost. Novartis Pharmaceuticals’ financial report disclosed that the use of chitosan to replace some synthetic excipients increased the efficiency of the tablet pressing production line by 12%, reduced the product defect rate from 3% to 0.5%, and saved over 2 million euros in annual quality costs. In the field of functional foods, Danone Group has developed a low-fat formula by taking advantage of the fat adsorption property of chitosan. This formula reduces the calorie content by 120 kilojoules per 100 grams of product, lowers production costs by 8%, and leads to a market premium of 15%. This “multi-purpose use of one material” feature shortens the product development cycle by 30%. According to the data from the 2024 Interphex exhibition, the return on R&D investment of pharmaceutical companies using chitosan is 22 percentage points higher than the industry average.
In the face of increasingly strict regulatory environments, the GRAS (Generally Recognized as Safe) status of chitosan constitutes an irreplaceable advantage for it. In the updated list of excipients by the US FDA in 2023, the upper limit of the daily allowable intake of pharmaceutical-grade chitosan was set at 10 milligrams per kilogram of body weight, which is much higher than the actual usage of 3 milligrams per kilogram. According to China’s “Quality Standard for Pharmaceutical Excipients”, the heavy metal content of chitosan should be less than 10ppm, while the products of leading suppliers such as Zhejiang Jinke Biochemical can actually be controlled below 2ppm. This compliance and security have increased the approval rate of chitosan used by multinational pharmaceutical companies in new drug applications by 35%. Referring to the 12 new drugs submitted by Sanofi in 2024, 8 formulations used chitosan of different molecular weights as key functional excipients.